Trevi Therapeutics
TRVI
TRVI
93 hedge funds and large institutions have $194M invested in Trevi Therapeutics in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
17% more capital invested
Capital invested by funds: $167M → $194M (+$27.5M)
0.7% more ownership
Funds ownership: 79.37% → 80.07% (+0.7%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
93
Holding in Top 10
–
Calls
$453K
Puts
$18K
Top Buyers
| 1 | +$5.39M | |
| 2 | +$2.76M | |
| 3 | +$2.02M | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$409K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$392K |
Top Sellers
| 1 | -$2.14M | |
| 2 | -$1.21M | |
| 3 | -$835K | |
| 4 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$775K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$604K |